Antithrombotic therapy in patients with peripheral artery diseases

Svetlikov A.V.^1,2, Sapelkin S.V.³, Ishpulaeva L.E.², Gorbunov G.N.²

1) Clinical Hospital No122 named after L.G. Sokolov under the Federal Biomedical Agency of the Russian Federation,
2) North-Western State Medical University named after I.I. Mechnikov under the RF Ministry of Public Health, Saint Petersburg,
3) National Medical Research Centre of Surgery named after A.V. Vishnevsky under the RF Ministry of Public Health, Moscow, Russia

Complications of cardiovascular diseases whose substrate is atherothrombosis continue to occupy leading positions in the structure of mortality worldwide. Peripheral artery diseases (PAD), in particular, are characterized by an especially unfavourable life prognosis for patients with cardiovascular diseases. In order to decrease the risks of ischaemic complications in patients with PAD, various approaches to antithrombotic therapy have over the last two decades been studied, with the resulting standard of therapy continuing to be acetylsalicylic acid. Even more difficult today is the task of selecting antithrombotic therapy in patients having endured revascularization.

KEY WORDS: atherosclerosis, atherothrombosis, peripheral artery disease, anticoagulants, antiaggregants.

P. 18

« Back